Camp4 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-51.79	-49.29	-44.19
Depreciation & Amortization	1.7	1.68	0.88
Stock-Based Compensation	4.03	2.91	1.38
Other Operating Activities	1.83	1.82	1.69
Change in Accounts Payable	0.17	-1.12	1.33
Change in Unearned Revenue	0.39	-	-
Change in Other Net Operating Assets	-1.88	-0.15	0.37
Operating Cash Flow	-45.56	-44.16	-38.54
Capital Expenditures	-0.44	-0.68	-4.03
Investing Cash Flow	-0.44	-0.68	-4.03
Long-Term Debt Issued	-	0.71	-
Long-Term Debt Repaid	-0.82	-0.59	-0.09
Net Debt Issued (Repaid)	-0.82	0.12	-0.09
Issuance of Common Stock	76.47	0.19	0.06
Other Financing Activities	-3.98	-	-
Financing Cash Flow	71.66	0.3	100.16
Net Cash Flow	25.66	-44.53	57.59
Free Cash Flow	-46	-44.83	-42.57
Free Cash Flow Margin	-7055.67%	-12809.43%	-
Free Cash Flow Per Share	-9.81	-113.51	-136.31
Levered Free Cash Flow	-26.54	-30.18	-
Unlevered Free Cash Flow	-26.52	-30.16	-
Change in Net Working Capital	-1.37	1.65	-

Updated Nov 21, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q